HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R01 Clinical Trial Optional)

The summary for the HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R01 Clinical Trial Optional) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R01 Clinical Trial Optional): The importance of prevention in combatting the opioid crisis is clear identifying and implementing effective strategies to prevent the onset of opioid misuse and use disorder and reducing the need to treat disorders yields positive individual, societal, and financial benefits. In 2020, 9.5 million people aged 12 or older misused opioids in the past year (NSDUH, 2021), suggesting that there are millions of people whose trajectories could have been changed, had they been exposed to an effective prevention strategy. Currently funded HEAL studies are testing whether existing programs shown to prevent or treat non-opioid substance use disorders might generalize to opioids. However, there remain many gaps in knowledge about how to deploy prevention services. Often effective strategies are not adopted, implemented, or scaled-up, limiting their reach and impact. There is a critical need for research to develop innovative strategies to implement and sustain prevention services that are affordable, practical, sustainable, and designed in partnership with end-users. To address these gaps, we propose an RFA with multiple receipt dates calling for investigator-initiated research that will address priorities in the implementation and sustainability of prevention services, and the creation of a prevention infrastructure.

Federal Grant Title:	HEAL Initiative: Research to Increase Implementation of Substance Use Preventive Services (R01 Clinical Trial Optional)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DA-24-067
Type of Funding:	Grant
CFDA Numbers:	93.213, 93.279, 93.866
CFDA Descriptions:	Information not provided
Current Application Deadline:	January 16th, 2026
Original Application Deadline:	January 16th, 2026
Posted Date:	September 22nd, 2023
Creation Date:	September 22nd, 2023
Archive Date:	February 21st, 2026
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	September 22nd, 2023

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-24-067.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Safety and Early Efficacy Studies of Psychedelic-Assisted Therapy for Chronic Pain in Olde...; • Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Agi...; • Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required); • Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data...; • Leveraging Data at Scale to Understand Natural Product Impacts on Whole Person Health (R01...; • Probiotics for Pediatric Illnesses; • Cam Practitioner Research Education Project Grant Partnership; • Complementary and Alternative Medicine Career Transition Award (K22)
More Grants from the National Institutes of Health: • Hazardous Materials Worker Health and Safety Training (U45 Clinical Trials Not Allowed); • Lasker Clinical Research Scholars Program (Si2/R00 Clinical Trial Optional); • Type 1 Diabetes TrialNet Clinical Network Hub (U01 Clinical Trial Not Allowed); • Advancing HIV service delivery through pharmacies and pharmacists (R21 Clinical Trial Opti...; • Advancing HIV service delivery through pharmacies and pharmacists (R01 Clinical Trial Opti...